TY - GEN
T1 - Uric acid and glucose level in high fructose high cholesterol induced Sprague-Dawley rats after therapy with Acalypha indica Linn. ethanol extract
AU - Krisnamurti, Desak Gede Budi
AU - Sinuraya, Fira Alyssa Gabriella
AU - Firsty, Tamara Ey
AU - Hakim, Rani Wardani
AU - Purwaningsih, Erni H.
N1 - Publisher Copyright:
© 2019 Author(s).
PY - 2019/12/10
Y1 - 2019/12/10
N2 - Diet with high fructose and cholesterol (HFHC) plays a role in the increasing incidence of diabetes mellitus and metabolic syndrome. Ethanol extract from Acalypha indica has been known to alleviate hyperglycemia and hyperuricemic conditions in rats induced by substances that destroy beta cells. This research aimed to evaluate its effect in rats induced by diet. Male Sprague-Dawley rats were divided into seven groups, six of which are given HFHC diet for 1,5 months. In the following month, rats were given therapy while diet continued. Therapy consisted of 250 mg/kg BW/day of Acalypha indica Linn. root's ethanol extract, 100 mg/kgBW/day of metformin, 30mg/kg BW/day of allopurinol, or combination. Lowest blood glucose value was found in group receiving both AI and metformin. No significant difference was found between pre- and post- therapy blood glucose in groups treated with AI (p=0,831), metformin (p=0,056), or both (p=0,908). Uric acid level was increased in all groups, with highest rate found in group receiving both allopurinol and AI. The difference in uric acid level between treatment group was 0.331. Whilst insignificant, ethanolic extract of Acalypha indica Linn. was observed to lower blood glucose in rats. Group treated with AI showed similar rise in uric acid level, with combination therapy showed highest rise. Further research with longer duration of induction and therapy will be required to better understand the hypoglycemic and antihyperuricemic effects exerted by AI.
AB - Diet with high fructose and cholesterol (HFHC) plays a role in the increasing incidence of diabetes mellitus and metabolic syndrome. Ethanol extract from Acalypha indica has been known to alleviate hyperglycemia and hyperuricemic conditions in rats induced by substances that destroy beta cells. This research aimed to evaluate its effect in rats induced by diet. Male Sprague-Dawley rats were divided into seven groups, six of which are given HFHC diet for 1,5 months. In the following month, rats were given therapy while diet continued. Therapy consisted of 250 mg/kg BW/day of Acalypha indica Linn. root's ethanol extract, 100 mg/kgBW/day of metformin, 30mg/kg BW/day of allopurinol, or combination. Lowest blood glucose value was found in group receiving both AI and metformin. No significant difference was found between pre- and post- therapy blood glucose in groups treated with AI (p=0,831), metformin (p=0,056), or both (p=0,908). Uric acid level was increased in all groups, with highest rate found in group receiving both allopurinol and AI. The difference in uric acid level between treatment group was 0.331. Whilst insignificant, ethanolic extract of Acalypha indica Linn. was observed to lower blood glucose in rats. Group treated with AI showed similar rise in uric acid level, with combination therapy showed highest rise. Further research with longer duration of induction and therapy will be required to better understand the hypoglycemic and antihyperuricemic effects exerted by AI.
KW - Acalypha indica Linn.
KW - allopurinol
KW - high-fructose-high-cholesterol
KW - hyperglycemic
KW - hyperuricemia
KW - metformin
UR - http://www.scopus.com/inward/record.url?scp=85076754152&partnerID=8YFLogxK
U2 - 10.1063/1.5139351
DO - 10.1063/1.5139351
M3 - Conference contribution
AN - SCOPUS:85076754152
T3 - AIP Conference Proceedings
BT - 4th Biomedical Engineering''s Recent Progress in Biomaterials, Drugs Development, Health, and Medical Devices
A2 - Lischer, Kenny
A2 - Abuzairi, Tomy
A2 - Rahman, Siti Fauziyah
A2 - Gozan, Misri
PB - American Institute of Physics Inc.
T2 - 4th International Symposium of Biomedical Engineering�s Recent Progress in Biomaterials, Drugs Development, Health, and Medical Devices, ISBE 2019
Y2 - 22 July 2019 through 24 July 2019
ER -
